- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01453218
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction (ATG_HVH)
Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
Physiopathologically pretransplant renal dysfunction is dependent on multifactorial causes, including hypoperfusion-derived functional renal insufficiency, hepatorenal syndrome or interstitial parenchymatous insufficiency. On top, intra- or post-transplant events, including hypoperfusion or calcineurin inhibitors nephrotoxicity may aggravate this situation.
At present MELD criteria favours allocation of organs to patients suffering from renal insufficiency, so at least 30% of the investigators liver transplant patients suffer from some degree of renal impairment pretransplant.
After liver transplant impaired renal function tends to recover partially or completely, unless advanced parenchymatous lesions are significantly involved as a major cause of renal dysfunction.
In this context, calcineurin inhibitors avoiding or sparing protocols may help in the recovery from renal insufficiency, improving long-term prognosis. The use of anti-CD25 antibodies is a good option, but provides a limited antirejection prophylaxis, limiting the use of these antibodies to a reduced cohort of liver transplant patients.
Polyclonal antibodies might provide an advantage in management of liver transplant patients with renal insufficiency, without increasing acute rejection episodes of the allograft efficacy and security evaluation of low nephrotoxicity immunosuppression, based on the use of ATeGe, in liver transplant candidates with pre-transplant renal dysfunction.
The aim of this study is to evaluate the efficacy and security use of immunosuppression based on ATeGe in liver transplant recipients with pre-transplant renal dysfunction.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Barcelona, Spanje, 08035
- Department of HPB Surgery and Transplants, Hospital Vall d´Hebron
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with moderate pre-transplant renal dysfunction as defined serum creatinine levels higher than 1.5 mg/dl or eGFR (MDRD-4) <60ml/min.
- First liver transplant, including splits liver transplant.
- Patients aged 18-70 years
- Without a prior contraindication for protocol biopsy of allograft.
Exclusion Criteria:
- Multiorgan transplantation and/or liver transplant from DCD and/or with ABO incompatibility.
- Uncontrolled concomitant infections (including HIV seropositivity) and/or diarrhoea, vomiting or active gastric ulcer.
- Fulminant hepatic insufficiency as first indication for liver transplant
- Hemodynamic instability prior to liver transplant.
- Recipient presenting present or previous neoplasia, except for non-metastatic basal or squamous cutaneous carcinoma or localized hepatocarcinoma with diameter <5 cm or < 3 known lesions with diameter <3 cm.
- Intolerance to study medication.
- Patients having received vaccination with attenuated living vaccines within the previous 4 weeks.
- Severe leukopenia (< 1.2 X 10E9/L) and/or thrombocytopenia (< 50x10E9/L) and/or lymphocyte counts (CD2+/CD3+) less than 10 cells/µl.
- Significant comorbidity.
- Breastfeeding or female patients at fertile age without negative pregnancy test and accepting the use of reliable fertility control method.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Geen tussenkomst: Basiliximab
Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
|
|
Actieve vergelijker: ATeGe-Fresenius
|
Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Renal function improvement after liver transplant
Tijdsspanne: Measurement will be performed at 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th and 28th day post-transplant, and 2nd, 3rd, 6th and 12th month post-transplant
|
Creatinine (mg/dL) and MDRD Glomerular Filtrate Rate (ml/min/1.73m2)
will be measured following the time frame described above
|
Measurement will be performed at 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th and 28th day post-transplant, and 2nd, 3rd, 6th and 12th month post-transplant
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Incidence of biopsy proven acute cellular rejection.
Tijdsspanne: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
If liver dysfunction is detected, percutaneous liver biopsy will be performed and histological severity will be assed following BANF criteria
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Patient and graft survival rates after 12 months, causes of death and retransplant
Tijdsspanne: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
|
Relationship between ATeGe doses, immunological variables (lymphocyte counts) and clinical adverse events (acute rejection,infections, HCV recurrence and de novo tumor)
Tijdsspanne: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
|
Incidence and severity of HCV infection recurrence, based on clinical and histological criteria.
Tijdsspanne: Once liver dysfunction is detected and one year post-transplant by protocol.
|
Once liver dysfunction is detected and one year post-transplant by protocol.
|
|
Evaluation of metabolic complications (diabetes mellitus, arterial hypertension and dyslipidemia)
Tijdsspanne: Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: ITXARONE BILBAO, PhD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Studie stoel: CRISTINA DOPAZO, PhD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Studie directeur: RAMON CHARCO, PHD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Studie stoel: MONICA MARTINEZ, PhD/MD, Department of Inmunology, Hospital Vall d´Hebron (Barcelona, Spain)
- Studie stoel: GONZALO SAPISOCHIN, PhD/MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Studie stoel: JOSE L LAZARO, MD, Department of HPB Surgery and Transplants, Hospital Vall d´Hebron (Barcelona, Spain)
- Studie stoel: HELENA ALLENDE, PhD/MD, Department of Histology, Hospital Vall d´Hebron (Barcelona, Spain)
Publicaties en nuttige links
Algemene publicaties
- Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011 Jul;24(7):640-50. doi: 10.1111/j.1432-2277.2011.01250.x. Epub 2011 Mar 23.
- Benitez CE, Puig-Pey I, Lopez M, Martinez-Llordella M, Lozano JJ, Bohne F, Londono MC, Garcia-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sanchez-Fueyo A. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant. 2010 Oct;10(10):2296-304. doi: 10.1111/j.1600-6143.2010.03164.x.
- Soliman T, Hetz H, Burghuber C, Gyori G, Silberhumer G, Steininger R, Muhlbacher F, Berlakovich GA. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 2007 Jul;13(7):1039-44. doi: 10.1002/lt.21185.
- Soliman T, Hetz H, Burghuber C, Gyori G, Silberhumer G, Steininger R, Muhlbacher F, Berlakovich GA. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int. 2007 May;20(5):447-52. doi: 10.1111/j.1432-2277.2007.00463.x. Epub 2007 Mar 2.
- Kim MJ, Tsinalis D, Franz S, Binet I, Gurke L, Mihatsch MJ, Steiger J, Thiel G, Dickenmann M. ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant. 2008;13(4):21-7.
- Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl. 2008 Jan;14(1):66-72. doi: 10.1002/lt.21309.
- Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 2004 Mar;10(3):404-7. doi: 10.1002/lt.20085.
- Dopazo C, Charco R, Caralt M, Pando E, Lazaro JL, Gomez-Gavara C, Castells L, Bilbao I. Low Total Dose of Anti-Human T-Lymphocyte Globulin (ATG) Guarantees a Good Glomerular Filtration Rate after Liver Transplant in Recipients with Pretransplant Renal Dysfunction. Can J Gastroenterol Hepatol. 2018 Aug 16;2018:1672621. doi: 10.1155/2018/1672621. eCollection 2018.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ATG-IRA-HVH.10
- 2011-000691-34 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Nierinsufficiëntie
-
Postgraduate Institute of Medical Education and...VoltooidType 1 HEPATO RENAL SYNDROOM (HRS)Indië
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
Children's Oncology GroupNational Cancer Institute (NCI)VoltooidHeldercellig niercelcarcinoom | Stadium III niercelkanker | Stadium IV niercelkanker | Heldercellig sarcoom van de nier | Papillair niercelcarcinoom | Rhabdoïde tumor van de nier | Stadium I niercelkanker | Niercelcarcinoom bij kinderen | Stadium II niercelkanker | Stadium I Renal Wilms-tumor | Stadium II... en andere voorwaardenVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico
Klinische onderzoeken op ATeGe-Fresenius
-
Medical University of ViennaVoltooid
-
University Health Network, TorontoHeart and Stroke Foundation of OntarioVoltooidHartziekte | Neurocognitieve achteruitgangCanada
-
Astellas Pharma China, Inc.VoltooidOntvangers van niertransplantatiesChina
-
Kyungpook National University HospitalMinistry of Health & Welfare, Korea; Fresenius Medical Care KoreaVoltooidNierfalen, chronisch | Aandoeningen geassocieerd met peritoneale dialyseKorea, republiek van
-
Lawson Health Research InstituteWestern University, CanadaVoltooidCardiale chirurgische ingrepen
-
Ullevaal University HospitalRikshospitalet University HospitalVoltooidExtracorporale stolling tijdens hemodialyseNoorwegen
-
UConn HealthDialysis Clinic, Inc.; Nipro Medical CorporationVoltooid
-
YUAN Wei-jieOnbekend
-
IRCCS Policlinico S. MatteoItalian Association for Pediatric Hematology OncologyOnbekendPediatrische patiënten met hematologische maligniteiten die in aanmerking komen voor HSCT door een niet-verwante vrijwilligerItalië
-
Rigshospitalet, DenmarkSnedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation; Danish... en andere medewerkersVoltooidCardiale magnetische resonantie | Gezonde individuen | T1-mappingDenemarken